Stabilis

Milrinone lactate



Nombre comercial

Corotrop	Alemania, Austria, Suecia, Suiza
Corotrope	Bélgica, Chile, Colombia, Eslovenia, España, Francia, Grecia, Hungría, Luxemburgo, Marruecos, Países Bajos, Polonia, Portugal, Rumania, Venezuela
Fisatrek	México
Milricor	Argentina, Turquía
Milrinona	Argentina, Chile, Colombia, Ecuador
Milrinone	Canadá, Estados Unidos de América, Francia, Gran Bretaña, Irán, Irlanda
Milron	Chile
Milrox	Colombia
Primacor	Australia, Brasil, Estados Unidos de América, Gran Bretaña, Irán, Malasia, México, Nueva Zelanda
Unacor	Hungría, Rumania
Vilmir	México

Estabilidad en solucion

		0,2 mg/ml	25°C	±	72			366
		0,2 mg/ml	25°C	±	72			366
	0.45	0,2 mg/ml	25°C	±	72			366
PVC		0,2 mg/ml	2-8°C		14			922
PVC		0,2 mg/ml	20-25°C	?	14			922
PVC		0,2 mg/ml	25°C	±	72			366
PVC		0,4 mg/ml	22°C-23°C		7			813
PVC		0,4 & 0,8 mg/ml	2-8°C		14			928
PVC		0,4 & 0,8 mg/ml	20-25°C		14			928
PVC		0,2 mg/ml	2-8°C		14			922
PVC		0,2 mg/ml	20-25°C	?	14			922

PVC		0,2 mg/ml	25°C	±	72				366
PVC		0,4 mg/ml	22°C-23°C		7				813
PVC		0,4 & 0,8 mg/ml	2-8°C		14				928
PVC		0,4 & 0,8 mg/ml	20-25°C		14				928
PVC	RL	0,4 mg/ml	22°C-23°C		7				813
PVC	0.45	0,2 mg/ml	25°C	±	72				366
PVC	0.45	0,4 mg/ml	22°C-23°C		7				813
PP		0,2 & 0,025 mg/ml	25°C	?	90				4216
PP		0,2 & 0,025 mg/ml	4°C	?	90				4216
PP	0.45	0,2 & 0,025 mg/ml	25°C	?	90				4216
PP	0.45	0,2 & 0,025 mg/ml	4°C	?	90				4216
PP	∅	1 mg/ml	25°C	?	90				4216
PP	∅	1 mg/ml	4°C	?	90				4216
?		0,6 mg/ml	25°C	?	24				4109
?		0,6 mg/ml	35°C	?	24				4109
?		0,6 mg/ml	4°C	?	7				4109
?		0,6 mg/ml	25°C	?	24				4109
?		0,6 mg/ml	35°C	?	24				4109
?		0,6 mg/ml	4°C	?	7				4109

Estabilidad en mezcla

		0,2 mg/ml	22°C-23°C		Insulin : 0,8 UI/ml	4	813
		0,2 mg/ml	22°C-23°C		Nitroprusside sodium : 0,4 mg/ml	4	813
		0,2 mg/ml	22°C-23°C		Nitroglycerin : 0,4 mg/ml	4	813
		0,2 mg/ml	22°C-23°C		Dopamine hydrochloride : 3,1 mg/ml	4	813
		0,2 mg/ml	22°C-23°C		Dobutamine hydrochloride : 4 mg/ml	4	813
		0,2 mg/ml	22°C-23°C		Epinephrine hydrochloride : 0,03 µg/ml	4	813
		0,2 mg/ml	22°C-23°C		Norepinephrine bitartrate : 0,03 mg/ml	4	813
		0,2 mg/ml	22°C-23°C		Ranitidine hydrochloride : 0,85 mg/ml	4	813
		0,2 mg/ml	22°C-23°C		Cimetidine hydrochloride : 2,9 mg/ml	4	813
		0,2 mg/ml	22°C-23°C		Pancuronium bromide : 0,46 mg/ml	4	813

		0,2 mg/ml	22°C-23°C		Atracurium besylate : 0,5 mg/ml	4		813
		0,2 mg/ml	22°C-23°C		Diltiazem hydrochloride : 0,5 mg/ml	4		813
		0,2 mg/ml	22°C-23°C		Bumetanide : 0,12 mg/ml	4		813
		0,2 mg/ml	22°C-23°C		Theophylline : 0,89 mg/ml	4		813
		0,2 mg/ml	22°C-23°C		Propofol : 5,3 mg/ml	4		813
		0,2 mg/ml	22°C-23°C		Heparin sodium : 59 UI/ml	4		813
		0,2 mg/ml	22°C-23°C		Morphine sulfate : 0,5 mg/ml	4		813
		0,2 mg/ml	22°C-23°C		Lorazepam : 0,1 mg/ml	4		813
		0,2 mg/ml	22°C-23°C		Midazolam hydrochloride : 0,5 mg/ml	4		813
		0,2 mg/ml	22°C-23°C		Fentanyl citrate : 25 µg/ml	4		813
		0,2 mg/ml	22°C-23°C		Isoprenaline hydrochloride : 3,7 mg/ml	4		813
		0,2 mg/ml	22°C-23°C		Vecuronium bromide : 0,52 mg/ml	4		813
		0,2 mg/ml	22°C-23°C		Rocuronium bromide : 1 mg/ml	4		813
		0,1 mg/ml	22°C-23°C		Digoxin : 125 µg/ml	4		191
		0,35 mg/ml	22°C-23°C		Digoxin : 50 µg/ml	4		191
		0,35 mg/ml	22°C-23°C		Propranolol hydrochloride : 0,3 mg/ml	4		191
		0,1 mg/ml	22°C-23°C		Propranolol hydrochloride : 0,5 mg/ml	4		191
		0,175 mg/ml	22°C-23°C		Quinidine gluconate : 5 mg/ml	4		191
		0,2 mg/ml	22°C-23°C		Quinidine gluconate : 10 mg/ml	4		191
		0,35 mg/ml	22°C-23°C		Verapamil hydrochloride : 1 mg/ml	4		191
		0,1 mg/ml	22°C-23°C		Verapamil hydrochloride : 1,25 mg/ml	4		191

Compatibilidades

		Milrinone lactate : 0,2 mg/ml	Pl 148	4835
		Milrinone lactate : 1 mg/ml Alprostadil : 500 µg/ml		4389
		Milrinone lactate : 0,2 mg/ml	Pl 148	4835
		Milrinone lactate : 0.8 mg/ml		813
		Milrinone lactate : 0,2 mg/ml		4507
		Milrinone lactate : 1 mg/ml	RL	4603
		Milrinone lactate		4987

	✓	Milrinone lactate : 0,5 mg/ml Alprostadil : 20 µg/ml	◆	4651
	✓	Milrinone lactate : 0,5 mg/ml Alprostadil : 20 µg/ml	◆	4491
	✓	Milrinone lactate : 0,4 mg/ml Amiodarone hydrochloride : 6 mg/ml	◆	1611
	✓	Milrinone lactate : 1 mg/ml Amiodarone hydrochloride : 1.8 mg/ml		4506
	✓	Milrinone lactate : 0.4 mg/ml Argatroban : 1 mg/ml	◆	1963
	✓	Milrinone lactate : 0.8 mg/ml Atracurium besylate : 2 mg/ml	◆	813
	✓	Milrinone lactate	▲	4987
	✓	Milrinone lactate : 1 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
	✓	Milrinone lactate : 0.2 mg/ml Bivalirudin : 5 mg/ml	◆	1713
↓	✗	Milrinone lactate Bumetanide		4987
	✓	Milrinone lactate : 0.8 mg/ml Bumetanide : 0.5 mg/ml	◆	813
	✓	Milrinone lactate : 1 mg/ml Bumetanide : 0,25 mg/ml		4506
	✓	Milrinone lactate : 0.4 mg/ml Caffeine : 10 mg/ml	◆	4837
	✓	Milrinone lactate : 1 mg/ml Caffeine : 10 mg/ml	∅	3964
	✓	Milrinone lactate : 0,4 mg/ml Caffeine citrate : 20 mg/ml	◆	4837
	✓	Milrinone lactate : 0.4 mg/ml Calcium chloride : 20 mg/ml	◆	4732
	✓	Milrinone lactate : 0.2 mg/ml Calcium chloride : 20 mg/ml	◆	4732
	✓	Milrinone lactate : 0.8 mg/ml Calcium gluconate : 200 mg/ml	◆	813
	✓	Milrinone lactate : 0,2 mg/ml Caspofungin acetate : 0,7 mg/ml	▲	2247
	✓	Milrinone lactate : 0,2 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	◆	4528
	✓	Milrinone lactate : 0,2 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	▲	4528
	✓	Milrinone lactate : 0,2 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
	✓	Milrinone lactate : 0,2 mg/ml Ceftaroline fosamil : 2,22 mg/ml	◆	3249
	✓	Milrinone lactate : 0,2 mg/ml Ceftaroline fosamil : 2,22 mg/ml	▲	3249
↓	✗	Milrinone lactate : 0.2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	◆	2269
?	✗	Milrinone lactate Ceftobiprole medocaril sodium		4650

		Milrinone lactate : 0.2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Milrinone lactate : 0.2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Milrinone lactate : 0.2 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Milrinone lactate : 0.2 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Milrinone lactate : 0,2 mg/ml Ceftriaxone disodium : 20 mg/ml		4144
		Milrinone lactate : 0.8 mg/ml Cimetidine hydrochloride : 12 mg/ml		813
		Milrinone lactate : 0.2 mg/ml Clonidine hydrochloride : 0.009 & 0.03 mg/ml		4130
		Milrinone lactate : 1 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Milrinone lactate Conivaptan		3715
		Milrinone lactate : 1 mg/ml Dexmedetomidine : 100 µg/ml		4389
		Milrinone lactate : 0.2 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Milrinone lactate : 0.1 & 0.35 mg/ml Digoxin : 50 & 125 µg/ml		191
		Milrinone lactate : 0.2 mg/ml Diltiazem hydrochloride : 1 mg/ml		314
		Milrinone lactate : 0.8 mg/ml Diltiazem hydrochloride : 2 mg/ml		813
		Milrinone lactate : 0.8 mg/ml Dobutamine hydrochloride : 16 mg/ml		813
		Milrinone lactate : 0.2 mg/ml Dobutamine hydrochloride : 4 mg/ml		314
		Milrinone lactate : 0.8 mg/ml Dopamine hydrochloride : 12.8 mg/ml		813
		Milrinone lactate : 0.2 mg/ml Dopamine hydrochloride : 3.2 mg/ml		314
		Milrinone lactate : 0,2 mg/ml Doripenem : 5 mg/ml		2262
		Milrinone lactate : 0,2 mg/ml Doripenem : 5 mg/ml		2262
		Milrinone lactate : 0.2 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
		Milrinone lactate : 0.8 mg/ml Epinephrine hydrochloride : 128 µg/ml		813
		Milrinone lactate : 1 mg/ml Epinephrine hydrochloride : 32 µg/ml		4506
		Milrinone lactate : 1 mg/ml Esmolol hydrochloride : 10 mg/ml		4389
		Milrinone lactate : 0.2 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Milrinone lactate : 0.8 mg/ml Fentanyl citrate : 100 µg/ml		813

		Milrinone lactate : 0.2 mg/ml Fentanyl citrate : 50 µg/ml		314
		Milrinone lactate : 0.2 mg/ml Fosfomycin : 30 mg/ml		4055
		Milrinone lactate : 0.2 mg/ml Fosfomycin : 30 mg/ml		4055
		Milrinone lactate : 0.2 mg/ml Furosemide : 10 mg/ml		314
		Milrinone lactate : 1 mg/ml Furosemide : 10 mg/ml		4506
		Milrinone lactate : 0.100 & 0.350 mg/ml Furosemide : 4 & 5 mg/ml		191
		Milrinone lactate Furosemide		4987
		Milrinone lactate : 0.8 mg/ml Heparin sodium : 200 UI/ml		813
		Milrinone lactate : 0.2 mg/ml Heparin sodium : 100 UI/ml		314
		Milrinone lactate : 0.2 mg/ml Hetastarch : 60 mg/ml		1721
		Milrinone lactate : 0.2 mg/ml Hydromorphone hydrochloride : 1 mg/ml		314
		Milrinone lactate : 0,2 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Milrinone lactate : 0,2 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Milrinone lactate : 0.8 mg/ml Insulin : 2 UI/ml		813
		Milrinone lactate : 0,25 mg/ml Insulin aspart : 1 UI/ml		1508
		Milrinone lactate : 0,25 mg/ml Insulin aspart : 1 UI/ml		1508
		Milrinone lactate : 0.2 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Milrinone lactate : 0.2 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Milrinone lactate : 0.8 mg/ml Isoprenaline hydrochloride : 0.016 mg/ml		813
		Milrinone lactate : 1 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Milrinone lactate : 0.2 mg/ml Labetalol hydrochloride : 2 mg/ml		314
		Milrinone lactate : 0.2 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Milrinone lactate : 0,2 mg/ml Levofloxacine : 5 mg/ml		4144
		Milrinone lactate : 1 mg/ml Levosimendan : 2,5 mg/ml		4389
		Milrinone lactate : 0.2 mg/ml Lorazepam : 0.5 mg/ml		314
		Milrinone lactate : 0.8 mg/ml Lorazepam : 0.4 mg/ml		813

	✓	Milrinone lactate : 0.8 mg/ml Magnesium sulfate : 80 mg/ml	◆	813
	✓	Milrinone lactate : 1 mg/ml Meropenem : 50 mg/ml	●	4319
	✓	Milrinone lactate : 0.2 mg/ml Metoprolol tartrate : 1 mg/ml	◆	2346
	✓	Milrinone lactate : 0.2 mg/ml Micafungin : 1.5 mg/ml	▲	2108
	✓	Milrinone lactate : 0.8 mg/ml Midazolam hydrochloride : 2 mg/ml	◆	813
	✓	Milrinone lactate : 0.2 mg/ml Midazolam hydrochloride : 2 mg/ml		314
	✓	Milrinone lactate : 0.2 mg/ml Morphine sulfate : 2 mg/ml		314
	✓	Milrinone lactate : 0.8 mg/ml Morphine sulfate : 2 mg/ml	◆	813
	✓	Milrinone lactate : 1 mg/ml N-acetylcysteine : 200 mg/ml	∅	3766
	✓	Milrinone lactate : 1 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
	✓	Milrinone lactate : 1 mg/ml Nicardipine hydrochloride : 0,4 mg/ml		4506
	✓	Milrinone lactate : 0.2 mg/ml Nicardipine hydrochloride : 1 mg/ml		314
	✓	Milrinone lactate : 0.2 mg/ml Nitroglycerin : 0.4 mg/ml		314
	✓	Milrinone lactate : 0.8 mg/ml Nitroglycerin : 1.6 mg/ml	◆	813
	✓	Milrinone lactate : 0.8 mg/ml Nitroprusside sodium : 1.6 mg/ml	◆	813
	✓	Milrinone lactate : 1 mg/ml Norepinephrine bitartrate : 0,032 mg/ml		4506
	✓	Milrinone lactate : 0.2 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
	✓	Milrinone lactate : 0.8 mg/ml Norepinephrine bitartrate : 0.128 mg/ml	◆	813
	✓	Milrinone lactate : 0.8 mg/ml Pancuronium bromide : 2 mg/ml	◆	813
	✓	Milrinone lactate : 1 mg/ml Paracetamol : 10 mg/ml		4742
	✓	Milrinone lactate : 0,03 mg/ml Pentoxifyllin : 5 mg/ml	▲	4538
	✓	Milrinone lactate : 0.2 mg/ml Plazomicin sulfate : 24 mg/ml	▲	4145
	✓	Milrinone lactate : 0.8 mg/ml Potassium chloride : 2000 mEq/l	◆	813
	✗	Milrinone lactate : 0.175 & 0.200 mg/ml Procainamide hydrochloride : 1 >> 4 mg/ml	◆	191
	✓	Milrinone lactate : 0.8 mg/ml Propofol : 20 mg/ml	◆	813
	✓	Milrinone lactate : 0.100 & 0.350 mg/ml Propranolol hydrochloride : 0.3 & 0.5 mg/ml	◆	191

		Milrinone lactate : 0.175 & 0.200 mg/ml Quinidine gluconate : 5 & 10 mg/ml		191
		Milrinone lactate : 0.2 mg/ml Ranitidine hydrochloride : 1 mg/ml		314
		Milrinone lactate : 0.8 mg/ml Ranitidine hydrochloride : 4 mg/ml		813
		Milrinone lactate : 0.8 mg/ml Rocuronium bromide : 4 mg/ml		813
		Milrinone lactate : 1 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
		Milrinone lactate : 0.4 mg/ml Sildenafil citrate : 0,6 mg/ml		4845
		Milrinone lactate : 0.8 mg/ml Sodium bicarbonate : 168 mg/ml		813
		Milrinone lactate : 0,2 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Milrinone lactate : 0.2 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Milrinone lactate : 0.2 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Milrinone lactate : 0.2 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Milrinone lactate : 0.2 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Milrinone lactate : 0.2 mg/ml Temocilline : 83.33 mg/ml		2231
		Milrinone lactate Temocilline		4470
		Milrinone lactate : 0.8 mg/ml Theophylline : 3.2 mg/ml		813
		Milrinone lactate : 0.2 mg/ml Thiopental sodium : 25 mg/ml		314
		Milrinone lactate : 1 mg/ml Thiopental sodium : 25 mg/ml		3767
		Milrinone lactate : 0.8 mg/ml Torsemide : 20 mg/ml		813
		Milrinone lactate : 0.2 mg/ml Vasopressin : 2 & 4 UI/ml		1801
		Milrinone lactate : 0.8 mg/ml Vecuronium bromide : 2 mg/ml		813
		Milrinone lactate : 0.2 mg/ml Vecuronium bromide : 1 mg/ml		314
		Milrinone lactate : 0.100 & 0.350 mg/ml Verapamil hydrochloride : 1 & 1.25 mg/ml		191

método de inyección

Bibliografía

	Tipo	Publicación
191	periódico	Riley CM. Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection. Am J Hosp Pharm 1988 ; 45: 2079-2091.
314	periódico	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
366	periódico	Wilson TD, Forde MD, Crain AVR, Dombrowski LJ, Joyce MA. Stability of milrinone in 0.45% sodium chloride, 0.9% sodium chloride, or 5% dextrose injections. Am J Hosp Pharm 1986 ; 43: 2218-2220.
813	periódico	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
922	periódico	Wong F, Gill MA. Stability of milrinone lactate 200 microg /mL in 5% dextrose injection and 0.9% sodium chloride injection. Int J Pharm Compound 1998 ; 2: 168-169.
928	periódico	Nguyen D, Gill MA, Wong F. Stability of milrinone lactate in 5% dextrose injection and 0.9% sodium chloride injection at concentrations of 400, 600 and 800 microg/mL. Int J Pharm Compound 1998 ; 2: 246-248.
1508	periódico	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1611	periódico	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	periódico	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1712	periódico	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	periódico	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	periódico	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1801	periódico	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.

1803	periódico	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1963	periódico	Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS. Compatibility of argatroban with selected cardiovascular agents. Am J Health-Syst Pharm 2004 ; 61: 2415-2418.
2108	periódico	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	periódico	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2231	periódico	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247	periódico	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	periódico	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	periódico	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2346	periódico	Newland A.M, Mauro V.F, Alexander K.S. Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents Am J Health-Syst Pharm 2009 ; 66: 986-987.
3012	periódico	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3216	periódico	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	periódico	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	periódico	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408	periódico	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3715	periódico	Mauro V.F, Howard M.S, Boddu S.H.S, Churchwell M.D. Compatibility of conivaptan injection with select cardiovascular medications. Am J Health-Syst Pharm 2014 ; 71:1534-1535
3766	periódico	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	periódico	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.

3824	periódico	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	póster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	póster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	póster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3964	periódico	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	periódico	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4109	periódico	Madfai F, Zaidi S, Ming L, Wanandy T, Patel R. Stability of milrinone in continuous ambulatory delivery devices. Am J Health-Syst Pharm 2018 ;75,9:241-245
4130	periódico	Koller AK, Krebs S, Dörje F. Untersuchungen zur Kompatibilität von Clonidin mit häufig eingesetzen Arzneimittel auf Intensivstationen. Pharmaceutics 2021 , 13, 21.
4144	periódico	Ross A, Boddu S, Mauro V, Churchwell M. Physical compatibility of milrinone with levofloxacin and ceftriaxone injection. EJHP 2018 ;75,14:1010-1012
4145	periódico	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4216	póster	Hook R, Riss V, Scharrer E, Robillard J, Law S, Walker SE. Stability of 1.0, 0.2 and 0.025 mg/mL Milrinone Solutions Stored in Syringes at 4ºC and at Room Temperature (25ºC). Sunnybrook 2019
4319	periódico	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	periódico	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4433	periódico	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4470	periódico	Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. Continuous versus intermittent infusion of temocillin in intensive care unit patient. Critical care 2005 ; 9(Suppl 1) P37
4491	periódico	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020

4506	periódico	Griffith S, Stapleton E, Padilla S, Mruk A, Thomas C. Physical compatibility of milrinone 1 mg/mL with select cardiovascular medications during simulated Y-site administration. Am J Health-Syst Pharm 2020 ;77,23:1938-1940.
4507	periódico	Ross E, Salinas A, Petty K, Her C, Carpenter J. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4528	periódico	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4538	periódico	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4603	periódico	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratorio	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4651	periódico	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4732	periódico	Kenneally A, Agbana P, Gardner B, Bae Y, Mitchell T, Beckman E. Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration. Am J Health-Syst Pharm 2023 80, 3;164–170
4742	periódico	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	periódico	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4835	periódico	Hammond S, Wignell A, Cooling P, Barrett D.A, Davies P. Plasma-Lyte 148 and Plasma-Lyte 148 + 5% glucose compatibility with commonly used critical care drugs. Intensive Care Medecine Experimental 2020 8:25.
4837	periódico	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.
4845	periódico	De Silva D.T.N, Strunk T, Petrovski M, Page-Sharp M, Moore B.R, Batty K.T. The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings. Pharmaceutics 2024 ;1 6, 419.
4987	Laboratorio	MILRINONE TILLOMED 1 mg/mL, solution injectable/pour perfusion - Résumé des caractéristiques du produit. TILLOMED PHARMA GMBH 2024

Diccionario

	Cardiotónico
	Nombre comercial
	Envase
	Concentración
	Conservación
	biosimilar
	Bibliografía
	Cloruro de sodio 0,9%
	Hora
0.45	Cloruro de sodio 0,45%
	A cubierto de la luz
?	No precisada
RL	Ringer lactato
Ø	Ninguno
	Estabilidad en mezcla
	Molécula
	Compatible
Pl 148	Plasmalyte 148 (Baxter)
	Nutrición parenteral (con lípidos)
	Incompatible
	Turbidez inmediata
	Precipitación después de 4 horas.
	Inestabilidad química
	método de inyección
	Perfusión continua
	Diccionario

	Inyectables
	Estabilidad en solucion
	Molécula
	Temperatura
	Duración de la estabilidad
	datos contradictorios
	Vidrio
	Con o sin luz
	Glucosa 5%
PVC	Cloruro de polivinilo
	Día
	Luz
	jeringa polipropileno
?	No precisado
	Solvente
	Compatibilidades
Pl 148	Plasmalyte 148 dextrose 5% (Baxter)
	Nutrición parenteral (libre de lípidos)
	Precipitación inmediata
	Incompatibilidad no especificada
	Agua para preparación inyectable
	específico disolvente
	Producción de burbujas de gas.
	Perfusión intravenosa
	Bibliografía